The Type II Glycoengineered Humanized Anti-CD20 Monoclonal Antibody MIL62 Combined with Orelabrutinib in Chinese Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Updated Results of a Multicenter, Phase I/IIa Trial

被引：0

作者：

Shi, Yuankai ^{[1
]}

Qin, Yan ^{[1
]}

Zang, Aimin ^{[2
]}

Li, Yufu ^{[3
]}

Yang, Yanli ^{[4
]}

Hui Liu ^{[5
]}

Gao, Sujun ^{[6
]}

Wang, Xinghe ^{[7
]}

Zhang, Weijing ^{[7
]}

Jin, Zhengming ^{[8
]}

Hui Zhou ^{[9
]}

Wang Hua-Qing ^{[10
]}

Min Wei ^{[11
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, Dept Med Oncol, Natl Canc Ctr,Natl Clin Res Ctr Canc,Canc Hosp, Beijing Key Lab Clin Study Anticanc Mol Targeted, Beijing, Peoples R China

[2] Hebei Med Univ, Affiliate Hosp, Dept Oncol, Baoding, Peoples R China

[3] Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Dept Hematol, Zhengzhou, Peoples R China

[4] Bengbu Med Coll, Affiliated Hosp 1, Bengbu, Peoples R China

[5] Beijing Hosp, Dept Hematol, Beijing, Peoples R China

[6] First Hosp Jilin Univ, Dept Hematol, Changchun, Peoples R China

[7] Capital Med Univ, Beijing Shijitan Hosp, Beijing, Peoples R China

[8] Soochow Univ, Affiliated Hosp 1, Suzhou, Peoples R China

[9] Cent South Univ, Affiliated Tumor Hosp, Xiangya Med Sch, Hunan Canc Hosp,Dept Lymphoma & Hematol, Changsha, Peoples R China

[10] Tianjin Peoples Hosp, Dept Oncol, Tianjin, Peoples R China

[11] Beijing Mabworks Biotech Co Ltd, Med Dept, Beijing, Peoples R China

来源：

BLOOD | 2022年 / 140卷

关键词：

MIL62; type II anti-CD20 monoclonal antibody; r/r B-NHL; DLBCL;

D O I：

10.1182/blood-2022-162984

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：9482 / 9483

页数：2

共 50 条

[1] Phase I study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody MIL62 in Chinese patients with relapsed/refractory CD20-positive B-cell non-Hodgkin's lymphoma
Shi, Y-K.
Song, Y.
Qin, Y.
Zhou, K.
Gao, Y.
Wang, M.
Wang, P.
Yin, Q.
Zhao, F.
Ma, G.
Li, F.
[J]. ANNALS OF ONCOLOGY, 2020, 31 : S652 - S652
[2] Preliminary phase I/II study results of orelabrutinib combined with MIL62 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma
Shi, Y-K.
Qin, Y.
Zhang, W.
Wang, X.
Liu, H.
Zang, A.
Yang, L.
Lin, D.
Li, F.
Zhu, H.
Zhao, R.
[J]. ANNALS OF ONCOLOGY, 2021, 32 : S778 - S778
[3] The Type II Glycoengineered Humanized Anti-CD20 Monoclonal Antibody MIL62 Combined with Lenalidomide in Chinese Patients with Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma: Results of a Multicenter, Single-Arm, Phase 1b/2 Trial
Shi, Yuankai
Qin, Yan
Song, Yongping
Zhou, Keshu
Zhou, Hui
Jing, Hongmei
Xiang, Ying
Wang, Zhao
Wang, Zhen
Zang, Aimin
Bai, Ou
Li, Zhenyu
Zhang, Huilai
[J]. BLOOD, 2021, 138
[4] A Phase I Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma
Christian, Beth
Alinari, Lapo
Earl, Christian Tyler
Wilding, Emily
Quinion, Carl
Lustberg, Mark
Benson, Don M., Jr.
Jones, Jeffrey A.
Byrd, John C.
Wegener, William A.
Goldenberg, David M.
Baiocchi, Robert A.
Blum, Kristie A.
[J]. BLOOD, 2010, 116 (21) : 1148 - 1149
[5] Polatuzumab vedotin, venetoclax, and an anti-CD20 monoclonal antibody in relapsed/refractory B-cell non-Hodgkin lymphoma
Yuen, Sam
Phillips, Tycel J.
Bannerji, Rajat
Marlton, Paula
Gritti, Giuseppe
Seymour, John F.
Johnston, Anna
Arthur, Christopher
Dodero, Anna
Sharma, Sunil
Hirata, Jamie
Musick, Lisa
Flowers, Christopher R.
[J]. AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (07) : 1281 - 1289
[6] Results of A Phase 1 Study of Milatuzumab, a Humanized Anti-CD74 Antibody, and Veltuzumab, a Humanized Anti-CD20 Antibody, In Patients with Relapsed and Refractory B-Cell Non-Hodgkin's Lymphoma
Christian, Beth
Alinari, Lapo
Jones, Jeffrey A.
Benson, Don M., Jr.
Flynn, Joseph M.
Porcu, Pierluigi
Lustberg, Mark E.
Phelps, Mitchell
Poi, Ming
Chung, Diana
Quinion, Carl
Byrd, John C.
Wegener, William
Goldenberg, David M.
Baiocchi, Robert A.
Blum, Kristie A.
[J]. BLOOD, 2011, 118 (21) : 1584 - 1584
[7] Humanized Anti-CD20 Antibody, Veltuzumab, in Refractory/Recurrent Non-Hodgkin's Lymphoma: Phase I/II Results
Morschhauser, Franck
Leonard, John P.
Fayad, Luis
Coiffier, Bertrand
Petillon, Marie-Odile
Coleman, Morton
Schuster, Stephen J.
Dyer, Martin J. S.
Horne, Heather
Teoh, Nick
Wegener, William A.
Goldenberg, David M.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (20) : 3346 - 3353
[8] Phase 2 trial of obinutuzumab, a humanized, glycoengineered monoclonal CD20 antibody, in combination with ifosfamide, carboplatin and etoposide for relapsed/refractory mature B-cell Non-Hodgkin lymphoma
Barth, Matthew J.
Hochberg, Jessica
Harrison, Lauren
Goldman, Stanton
Flowers, Allyson
Cairo, Mitchell S.
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2018, 182 : 48 - 49
[9] The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma
Christian, Beth A.
Poi, Ming
Jones, Jeffrey A.
Porcu, Pierluigi
Maddocks, Kami
Flynn, Joseph M.
Benson, Don M.
Phelps, Mitch A.
Wei, Lai
Byrd, John C.
Wegener, William A.
Goldenberg, David M.
Baiocchi, Robert A.
Blum, Kristie A.
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 (05) : 701 - 710
[10] Phase 1 study results of the type II glycoengineered humanized anti-CD20 monoclonal antibody obinutuzumab (GA101) in B-cell lymphoma patients
Salles, Gilles
Morschhauser, Franck
Lamy, Thierry
Milpied, Noel
Thieblemont, Catherine
Tilly, Herve
Bieska, Gabi
Asikanius, Elina
Carlile, David
Birkett, Joe
Pisa, Pavel
Cartron, Guillaume
[J]. BLOOD, 2012, 119 (22) : 5126 - 5132

← 1 2 3 4 5 →